Table 3. Characteristics and Costs of Biosimilar Comparative Efficacy Trials.
| Characteristic | No. | Median (IQR) | |||
|---|---|---|---|---|---|
| Trials | Biosimilar products | Patients enrolled, No. | Treatment duration, wk | Estimated costa | |
| Overall | 29 | 23 | 504 (258-612) | 52 (28-68) | 20.8 (13.8-35.3) |
| By trial phase | |||||
| Phase 1 | 5 | 2 | 122 (60-256) | 15 (14-15) | 1.9 (1.6-1.9) |
| Phase 3 | 24 | 21 | 538 (372-644) | 55 (46-78) | 27.6 (18.0-36.7) |
| By therapeutic category | |||||
| Anti-TNF | 10 | 9 | 564 (526-606) | 61 (52-78) | 19.0 (14.0-32.8) |
| Oncology | 10 | 9 | 573 (394-719) | 60 (52-156) | 36.7 (34.5-71.3) |
| Hematopoietic | 9 | 5 | 218 (122-303) | 25 (15-28) | 2.1 (1.9-15.6) |
Abbreviations: IQR, interquartile range; TNF, tumor necrosis factor.
a
In millions of US dollars.